These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

764 related articles for article (PubMed ID: 30621042)

  • 1. Treatment of Parkinson's Disease through Personalized Medicine and Induced Pluripotent Stem Cells.
    Stoddard-Bennett T; Reijo Pera R
    Cells; 2019 Jan; 8(1):. PubMed ID: 30621042
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stem cell therapy for Parkinson's disease: safety and modeling.
    Stoddard-Bennett T; Pera RR
    Neural Regen Res; 2020 Jan; 15(1):36-40. PubMed ID: 31535640
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Using Patient-Derived Induced Pluripotent Stem Cells to Identify Parkinson's Disease-Relevant Phenotypes.
    Sison SL; Vermilyea SC; Emborg ME; Ebert AD
    Curr Neurol Neurosci Rep; 2018 Oct; 18(12):84. PubMed ID: 30284665
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Understanding Parkinson's Disease through the Use of Cell Reprogramming.
    Playne R; Connor B
    Stem Cell Rev Rep; 2017 Apr; 13(2):151-169. PubMed ID: 28083784
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dissecting the non-neuronal cell contribution to Parkinson's disease pathogenesis using induced pluripotent stem cells.
    Pons-Espinal M; Blasco-Agell L; Consiglio A
    Cell Mol Life Sci; 2021 Mar; 78(5):2081-2094. PubMed ID: 33210214
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Progress in Dopaminergic Cell Replacement and Regenerative Strategies for Parkinson's Disease.
    Chen W; Huang Q; Ma S; Li M
    ACS Chem Neurosci; 2019 Feb; 10(2):839-851. PubMed ID: 30346716
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induced pluripotent stem cell (iPSC)-derived dopaminergic models of Parkinson's disease.
    Beevers JE; Caffrey TM; Wade-Martins R
    Biochem Soc Trans; 2013 Dec; 41(6):1503-8. PubMed ID: 24256244
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potential application of induced pluripotent stem cells in cell replacement therapy for Parkinson's disease.
    Chen LW; Kuang F; Wei LC; Ding YX; Yung KK; Chan YS
    CNS Neurol Disord Drug Targets; 2011 Jun; 10(4):449-58. PubMed ID: 21495962
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Engraftable Induced Pluripotent Stem Cell-Derived Neural Precursors for Brain Repair.
    Zygogianni O; Kouroupi G; Taoufik E; Matsas R
    Methods Mol Biol; 2020; 2155():23-39. PubMed ID: 32474865
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Redefining Parkinson's disease research using induced pluripotent stem cells.
    Pu J; Jiang H; Zhang B; Feng J
    Curr Neurol Neurosci Rep; 2012 Aug; 12(4):392-8. PubMed ID: 22622410
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modeling Parkinson's Disease Using Patient-specific Induced Pluripotent Stem Cells.
    Li H; Jiang H; Zhang B; Feng J
    J Parkinsons Dis; 2018; 8(4):479-493. PubMed ID: 30149462
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Replacing what's lost: a new era of stem cell therapy for Parkinson's disease.
    Fan Y; Winanto ; Ng SY
    Transl Neurodegener; 2020; 9():2. PubMed ID: 31911835
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dopaminergic differentiation using pluripotent stem cells.
    Momčilović O; Montoya-Sack J; Zeng X
    J Cell Biochem; 2012 Dec; 113(12):3610-9. PubMed ID: 22807388
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cell Therapy for Parkinson's Disease.
    Shastry S; Hu J; Ying M; Mao X
    Pharmaceutics; 2023 Nov; 15(12):. PubMed ID: 38139997
    [TBL] [Abstract][Full Text] [Related]  

  • 15. What we can learn from iPSC-derived cellular models of Parkinson's disease.
    Caiazza MC; Lang C; Wade-Martins R
    Prog Brain Res; 2020; 252():3-25. PubMed ID: 32247368
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Generation of Naivetropic Induced Pluripotent Stem Cells from Parkinson's Disease Patients for High-Efficiency Genetic Manipulation and Disease Modeling.
    Hu Z; Pu J; Jiang H; Zhong P; Qiu J; Li F; Wang X; Zhang B; Yan Z; Feng J
    Stem Cells Dev; 2015 Nov; 24(21):2591-604. PubMed ID: 26218671
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impairment of proteasome and anti-oxidative pathways in the induced pluripotent stem cell model for sporadic Parkinson's disease.
    Chang KH; Lee-Chen GJ; Wu YR; Chen YJ; Lin JL; Li M; Chen IC; Lo YS; Wu HC; Chen CM
    Parkinsonism Relat Disord; 2016 Mar; 24():81-8. PubMed ID: 26797011
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Parkinson's Disease-Associated Changes in the Expression of Neurotrophic Factors and their Receptors upon Neuronal Differentiation of Human Induced Pluripotent Stem Cells.
    Novosadova EV; Nenasheva VV; Makarova IV; Dolotov OV; Inozemtseva LS; Arsenyeva EL; Chernyshenko SV; Sultanov RI; Illarioshkin SN; Grivennikov IA; Tarantul VZ
    J Mol Neurosci; 2020 Apr; 70(4):514-521. PubMed ID: 31820346
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pluripotent Stem Cells for Modelling and Cell Therapy of Parkinson's Disease.
    Lebedeva OS; Lagarkova MA
    Biochemistry (Mosc); 2018 Sep; 83(9):1046-1056. PubMed ID: 30472943
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induced pluripotent stem cells: a tool for modeling Parkinson's disease.
    Bose A; Petsko GA; Studer L
    Trends Neurosci; 2022 Aug; 45(8):608-620. PubMed ID: 35667922
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.